phase 2, 0 NCT04787211
amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) vs. placebo
COVID-19 mild to moderate
CORIMUNO-NIVO, 0 NCT04343144
anti-PD-1 antibody vs. standard of care
COVID-19 mild to moderate
CORIMMUNO-BEVA, 0 NCT04344782
bevacizumab vs. standard of care
COVID-19 mild to moderate
Suzuki, 2021
casirivimab/imdevimab (Ronapreve) vs. control
COVID-19 mild to moderate
Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 NCT04426695
casirivimab/imdevimab (Ronapreve) vs. placebo
COVID-19 mild to moderate
Libster, 2020 NCT04479163
convalescent plasma treatment vs. placebo
COVID-19 mild to moderate
CORIPLASM, 0 NCT04345991
convalescent plasma treatment vs. standard of care
COVID-19 mild to moderate
PLACID, 2020 CTRI/2020/04/024775
convalescent plasma treatment vs. standard of care
COVID-19 mild to moderate
NCT04343768, 0 NCT04343768
interferon vs. interferon
COVID-19 mild to moderate
Hassaniazad, 2020 IRCT20200506047323N3
interferon vs. lopinavir/ritonavir plus interferon ß-1a
COVID-19 mild to moderate
COVID-Lambda, 0 NCT04331899
interferon vs. standard of care
COVID-19 mild to moderate
Fu, 2020 ChiCTR2000030262
interferon / TFF2 vs. standard of care
COVID-19 mild to moderate
Jagannathan, 2020 NCT04331899
peginterferon vs. placebo
COVID-19 mild to moderate
Pandit, 2021 CTRI/2020/06/026087
pegylated interferon-α2b vs. standard of care
COVID-19 mild to moderate
Shashi Bhushan, 2021 CTRI/2020/12/029855
pegylated interferon-α2b vs. standard of care
COVID-19 mild to moderate
Lattmann, 2021 CTRI/2020/10/028423
PNB001 vs. standard of care
COVID-19 mild to moderate
POLYCOR phase IIb (Gaborit), 2021 NCT04453384
XAV-19 vs. placebo
COVID-19 mild to moderate